Francisco Arath Ruíz-Velázquez

Dr. Francisco Arath Ruíz-Velázquez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Salud Pública de México
Verified
Journal Article
Open access
PDF file
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
FRFrancisco Arath Ruíz-Velázquez
Francisco Arath Ruíz-Velázquez
AHAnaid Herrerías-García
Anaid Herrerías-García
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
ELElia Lara-Lona
Elia Lara-Lona
LALauro Fabian Amador-Medina
Lauro Fabian Amador-Medina

28 April 2024 in Genes
Verified
Journal Article
Open access
PDF file
Pablo Romero-MorelosPablo Romero-Morelos
Pablo Romero-Morelos
AGAna Lilia González-Yebra
Ana Lilia González-Yebra
AHAnaid Herrerías-García
Anaid Herrerías-García
FRFrancisco Arath Ruíz-Velázquez
Francisco Arath Ruíz-Velázquez
LBLuis Jonathan Bueno-Rosario
Luis Jonathan Bueno-Rosario
BGBeatriz Gonzalez-Yebra
Beatriz Gonzalez-Yebra
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of the Philadelphia chromosome, a product of the reciprocal translocation t(9;22)(q34;q11), in the BCR and ABL genes. These rearrangements in both genes lead to the formation of various fusion mRNA products, with preferential expression of b2a2, b3a2, and other BCR::ABL1 mRNA variants, combined with additional chromosomal abnormalities. Notably, the distribution and frequency of different mRNA variants vary in different populations. However, studies concerning this in Mexico are limited, and the results have been inconclusive. This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.